PDCD1 and neoplasm: showed in mouse models that TDLNs are enriched with tumor‐specific PD‐1+ T cells, and PD‐L1 blockade targeting TDLNs enhances anti‐tumor T cell immunity by mobilizing Tpex to the tumor site, leading to improved tumor control.[141] Prokhnevska et al.